Table 1.
Sociodemographic and clinical characteristics of the patients (N = 1212).
Table 2.
Internal consistency reliability, test-retest reliability, and floor/ceiling effect of the SF-36v2 and the QOL-DAv2.0 (N = 1212).
Table 3.
Convergent validity † and discriminant validity ‡ of the SF-36v2 and the QOL-DAv2.0: Multitrait-multimethod (MTMM) correlation matrix (spearman γ) (N = 1212).
Table 4.
Sensitivity of the SF-36v2 and the QOL-DAv2.0 in self-evaluated health status: scores (mean ± SD) and relative efficiency (RE) (N = 1212).
Table 5.
Sensitivity of the SF-36v2 and the QOL-DAv2.0 in average daily dose of methadone intake (mg): scores (mean ± SD) and relative efficiency (RE) (N = 1212).
Table 6.
Responsiveness of the SF-36v2 and the QOL-DAv2.0: scores (mean ± SD) and standardized response mean (SRM) stratified on improvement, status quo, or deterioration in health status (N = 1010).